NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









iOnctura

iOnctura

Private
GenevaHealthcare & Life Scienceshttps://www.ionctura.com

Last Round

Series B

Jun 20, 2024

Est. Valuation

$139.6M

Total Funding Raised

$111.26M

Company Overview

iOnctura is a biotechnology company focused on developing next-generation bio-molecules for the treatment of cancer and fibrosis through innovative therapeutics that target immunosuppression in the tumor microenvironment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

clinical-stage biotechsmall molecule drugsprecision oncologyPI3Kδ inhibitoroncology therapeuticscancer drugsautotaxin inhibitortumor microenvironmentoral cancer therapydrug developmentfibrotic cancersfirst-in-class drugsallosteric modulatoruveal melanomanon-small cell lung cancerNSCLCprimary myelofibrosisTGF-β pathway inhibitor

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

iOnctura Comparables

Compare iOnctura with similar companies based on industry and business-model similarity.

iOnctura comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

iOnctura Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 20, 2024
GrantDec 20, 2022
DebtSep 28, 2022
Series A ExtensionJul 14, 2020
Series AJan 23, 2020
Seed
Jun 20, 2017

Key People

Founding team and executive leadership

David Seeberger

Chief Financial Officer

Executive Team

Steven Sciuto

Chief Financial Officer

Executive Team

Michelle Tsai

Chief Operating Officer

Executive Team

iOnctura Investors

Notable investors and investment history

iOnctura investors
InvestorRounds
European Innovation CouncilGrant, Series B
XGEN VentureSeries B
SynconaSeries B
FongitDebt
3B FUTURE Health FundSeries B, Series A Extension
M VenturesSeries A, Series B
VI PartnersSeries B, Series A, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 9, 2026

    CEO to present at the 2026 J.P. Morgan Healthcare Conference.

  • Jul 1, 2025

    Collaborating with Dana-Farber Cancer Institute to expand US clinical trials.

iOnctura Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

iOnctura Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about iOnctura's valuation, stock price, and market status.

Firmographic Details

HeadquartersGeneva
Employee Range34
Year Founded2017
Last FundingJun 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.